SIAG
TVRD

Safeguard Investment Advisory Group’s Tvardi Therapeutics TVRD Stock Holding History

Safeguard Investment Advisory Group’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3
Closed -$1K – 757
2020
Q4 		$1K Buy
+3
New +$1.57K ﹤0.01% 699

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Safeguard Investment Advisory Group's TVRD Position: Q1 2021 in Review

Safeguard Investment Advisory Group sold out of Tvardi Therapeutics (TVRD) in Q1 2021, closing a stake of 3 shares — an estimated $1K sold.

Safeguard Investment Advisory Group first reported a position in TVRD in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 168 funds tracked by Wall St. Rank hold TVRD as of Q1 2021.

  • Safeguard Investment Advisory Group reported no remaining Tvardi Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Safeguard Investment Advisory Group sold 3 Tvardi Therapeutics shares in Q1 2021, an estimated $1K.
  • Safeguard Investment Advisory Group first reported a position in Tvardi Therapeutics in Q4 2020 and held it in 1 quarter.
  • Safeguard Investment Advisory Group's Tvardi Therapeutics position peaked at $1K in Q4 2020.
  • 168 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2021.

Based on Safeguard Investment Advisory Group's 13F filing for Q1 2021, filed 10 May 2021.